Xtandi Patent Protection
7 patents · Astellas Pharma Inc., Pfizer Inc.
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 9126941 | Orange Book listed patent | Astellas Pharma Inc. | May 15, 2026 | Expired |
| 8183274 | Orange Book listed patent | Astellas Pharma Inc. | Aug 24, 2026 | 0.2y left |
| 7709517 | Drug substance & product patent | Astellas Pharma Inc. | Aug 13, 2027 | 1.1y left |
| 12502357 | Orange Book listed patent | Astellas Pharma Inc. | Sep 11, 2033 | 7.2y left |
| 12447128 | Orange Book listed patent | Astellas Pharma Inc. | Sep 11, 2033 | 7.2y left |
| 11839689 | Drug product (formulation / method-of-use) patent | Astellas Pharma Inc. | Sep 11, 2033 | 7.2y left |
| 12161628 | Orange Book listed patent | Astellas Pharma Inc. | Feb 23, 2037 | 10.7y left |
Related Drug Patent Expirations
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
3 patents · earliest expires 2027 · Pfizer Inc.
22 patents · earliest expires 2028 · Pfizer Inc.
0 patents · Amgen Inc.
17 patents · earliest expires 2026 · AstraZeneca AB
33 patents · earliest expires 2026 · Novo Nordisk A/S
For Xtandi, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Xtandi’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.